15
Participants
Start Date
September 16, 2024
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2026
Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)
Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
Insulin regular, 32 mU/m2/min (hyperinsulinemia)
Insulin infusion to induce hyperinsulinemia for assessment of insulin sensitivity
Octreotide Acetate, 6-45 ng/kg/min
Suppression of endogenous insulin secretion
Dextrose 20 % in Water
Production of steady-state plasma glucose (SSPG) reflective of insulin sensitivity at hyperinsulinemia
Glucagon, 0-0.5 ng/kg/min
Replacement of endogenous glucagon suppressed by octreotide. (Use is optional at the PI's discretion.)
RECRUITING
Columbia University Irving Medical Center, New York
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
University of Pisa
OTHER
Columbia University
OTHER